ascopubs.org

Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival ...

Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does ...
ascopubs.org

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in ...

In the WSG-ADAPT-TP (ClinicalTrials.gov identifier: NCT01779206) phase II trial, 375 centrally reviewed patients with hormone receptor-positive (HR+)/HER2+ EBC (clinical stage I-III) were randomly ...
Healio

De-escalated neoadjuvant paclitaxel, dual HER2 blockade effective in breast cancer subtype

Please provide your email address to receive an email when new articles are posted on . A de-escalated, 12-week neoadjuvant treatment regimen of dual HER2 blockade with pertuzumab and trastuzumab plus ...
Finanznachrichten

EXACT SCIENCES CORP: Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients

The combined analysis, called ADAPT Triad, is expected to include data from approximately 3,000 German patients enrolled in two ongoing WSG ADAPT trials and one WSG registry study. All patients ...
Healio

VIDEO: Some breast cancer patients may be treated without chemotherapy

In this video, Daphna Yael Spiegel, MD, an instructor in radiation oncology at Beth Israel Deaconess Medical Center, spoke with Healio about data from the WSG-ADAPT HER2+/HR– trial presented at ASCO ...
PR Newswire

Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients

ADAPT Triad minimal residual disease analysis study intended to evaluate the association between circulating tumor DNA (ctDNA) positivity and recurrence intervals MADISON, Wis., Aug. 3, 2022 ...